UCB SA (EUR)
UCB
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
IndustryBiotechnology
Day Range66.30 | 67.88
52-Wk Range62.26 | 80.06
Last Close66.86
Mkt Cap (m)12,594.20
Dividend yield1.81%
ISINBE0003739530
Volume310,741
Exchange VenueBRU

Company Profile

UCB SA is engaged in the development of novel therapies for the treatment of central nervous system and immunological diseases.

Key Information
Price/Earning19.27
Price/Book1.94
Price/Sales2.68
P/CF13.23
Rev Growth (3 year avg)6.12
EPS Growth (3 year avg)0.09
Operating Margin % 23.83
Net Margin %17.27
Return on Equity13.20
Debt/Equity0.24

Legal Documents

Annual Report
en 31/12/2018

Financials

Income Statement
EUR201320142015201620172018
Revenue (m)3,4113,3443,8764,1784,5304,632
Operating Income (m)4653686389211,1151,104
Net Income (m)207209623520753800
Basic EPS1.141.103.252.764.004.24
Avg. Diluted Shares Outstanding (m)182190192188188188
Balance Sheet
EUR201320142015201620172018
Current Assets (m)2,4212,5012,8382,3312,6772,950
Non Current Assets (m)7,4867,6478,1187,8817,2407,564
Total Assets (m)9,90710,14810,95610,2129,91710,514
Current Liabilities (m)2,3362,3363,0612,4181,9492,238
Total Liabilities (m)------
Total Equity (m)4,6035,0025,6725,5845,8136,310
Cash Flows
EUR201320142015201620172018
Operating Cash Flows (m)2985122454279271,089
Capital Expenditure (m)-353-161-146-138-209-341
Figures are quoted in EUR unless stated otherwise
-0.30 (-0.45%)
66.56
Last Price